ETF Building Blocks Content Hub Consolidation Could Come Calling for Biotech in 2022 By Tom LydonJanuary 5, 2022
ETF Building Blocks Content Hub Memeification of Biotech Stocks Shines Light on This ETF By Tom LydonNovember 24, 2021
ETF Building Blocks Content Hub Biotech Ready to Participate in Healthcare Bullishness By Tom LydonOctober 29, 2021
ETF Building Blocks Content Hub Drug Price Debate May Not Hinder Biotech ETFs After All By Tom LydonSeptember 16, 2021
ETF Building Blocks Content Hub Biotech Stocks Have Colds, but They Can Heal By Tom LydonSeptember 13, 2021
Alternatives Content Hub Duff & Phelps Introduces Actively Managed Clean Energy ETF, ‘VCLN’ By Aaron NeuwirthAugust 4, 2021
ETF Building Blocks Content Hub Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
Alternatives Content Hub ETFs that Could Benefit from Biden’s Infrastructure Plan By Ian YoungJuly 8, 2021
Alternatives Content Hub Active Management Adds to Allure of Preferred Stocks By Tom LydonJune 25, 2021
Alternatives Content Hub Consider a Hidden Gem in International Dividend ETFs By Tom LydonJune 14, 2021
ETF Building Blocks Content Hub Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
ETF Building Blocks Content Hub As Biotech Consolidation Heats up, ‘SBIO’ Could Be a Winner By Tom LydonMay 24, 2021
Alternatives Content Hub Active Municipal Bond ETFs: A Rare, Overlooked Asset Class By Tom LydonMay 24, 2021
Alternatives Content Hub Impact and Income: Are Utilities the Next Impact Investments? By Tom LydonApril 20, 2021
New ETFs Newfleet and Virtus ETFs Launch Securitized Debt ETF, ‘VABS’ By Aaron NeuwirthFebruary 10, 2021
ETF Building Blocks Content Hub Capture Medical Breakthroughs and Big Acquisition Bucks with ‘SBIO’ By Tom LydonFebruary 10, 2021
ETF Building Blocks Content Hub ALPS ‘SBIO’ ETF: Trial Progress Meets Investing Success By Tom LydonJanuary 25, 2021
